Time course of contrast enhancement patterns after Gd-BOPTA in correlation to myocardial infarction and viability: a feasibility study.
Our objective was to analyze contrast enhancement patterns (CEP) and their time course after myocardial infarction (MI) following injection of Gd-BOPTA in correlation with recovery of regional function. Seven patients with subacute MI (18 +/- nine days) were examined before, as well as three and six (n = six) months after, revascularization of the infarct-related artery. Regional wall motion abnormalities were assessed by cine-MRI, and repetitive images of one representative slice were acquired up to 45 minutes after 0.05 mmol/kg Gd-BOPTA using a T1-w TSE-sequence. Two patients showed mid-wall/subendocardial, one patient subendocardial enhancement of MI associated with mechanical improvement after revascularization. Three patients without improvement revealed a mid-wall hypoenhanced zone within the first five minutes after injection, which was unchanged at follow-up. One patient with partial functional improvement showed transmural enhancement and a mid-wall hypoenhanced zone in adjacent areas. With this feasibility study, we concluded that mid-wall and/or subendocardial enhancement after Gd-BOPTA was associated with viable myocardium, whereas detection of microvascular obstruction correlating with scar formation is suggested by mid-wall hypoenhancement within the first five minutes after injection.
Sandstede
J J
JJ
Institut für Röntgendiagnostik und Medizinische Klinik, Universität Würzburg, Würzburg, Germany. joern.sandstede@mail.uni-wuerzburg.de
Beer
M
M
Lipke
C
C
Pabst
T
T
Kenn
W
W
Harre
K
K
Neubauer
S
S
Hahn
D
D
D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000493:pharmacokinetics; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007089:Image Enhancement; D019028:Magnetic Resonance Imaging, Cine; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology*; D009942:Organometallic Compounds / Q000493:pharmacokinetics; D013997:Time Factors
D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine